Novartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

BERLIN ― Swiss drugmaker Novartis nudged up its full-year earnings forecast on Thursday, citing strong revenue growth from products such as breast cancer drug Kisqali during the second quarter.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year ...

Novartis could soon face generic competition for Entresto after judge's ruling.

For the second quarter, Entresto sales climbed 22% at constant currency to $2.36 billion, contributing to an 11% increase for the group as a whole to $14.05 billion. Novartis cited Kisqali and ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Sales of Kisqali, which treats metastatic breast cancer, surged 64% globally on a constant currency basis in the three months to June, the company said in its second-quarter sales report. That ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...